Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017–2021

References

• Zhao Y, Han M, Ma Y, et al. Progress towards the 90-90-90 targets for controlling HIV — China, 2018. China CDC Wkly. 2019;1(1):5–9. doi: 10.46234/ccdcw2019.003
   PubMedGoogle Scholar
• Wu Z, Chen J, Scott SR, et al. History of the HIV Epidemic in China. Curr HIV/AIDS Rep. 2019;16(6):458–466. doi: 10.1007/s11904-019-00471-4
   PubMed Web of Science ®Google Scholar
• Cao W, Hsieh E, Li T. Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges. Curr HIV/AIDS Rep. 2020;17(1):26–34. doi: 10.1007/s11904-019-00478-x
   PubMed Web of Science ®Google Scholar
• Haris M, Rizwan AR. Four decades of HIV: Global trends, testing assays, treatment, and challenges. Zoonoses. 2024;4(1):2. doi: 10.15212/ZOONOSES-2023-0039
   Google Scholar
• Zuo L, Liu K, Liu H, et al. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017). EClinicalMedicine. 2020;18:100238. doi: 10.1016/j.eclinm.2019.100238
   PubMedGoogle Scholar
• Yerly S, Calmy A. Time to overcome pretreatment HIV drug resistance. Lancet Infect Dis. 2018;18(3):239–240. doi: 10.1016/S1473-3099(17)30709-0
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang M, Zhang R, et al. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China. BMC Infect Dis. 2019;19(1):313. doi: 10.1186/s12879-019-3927-1
   PubMedGoogle Scholar
• Li D, Chen H, Li H, et al. HIV-1 pretreatment drug resistance and genetic transmission network in the southwest border region of China. BMC Infect Dis. 2022;22(1):741. doi: 10.1186/s12879-022-07734-3
   PubMed Web of Science ®Google Scholar
• Chen H, Hao J, Hu J, et al. Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study. JMIR Public Health Surveill. 2023;9:e50894. doi: 10.2196/50894
   PubMedGoogle Scholar
• Kang R-H, Liang S-J, Ma Y-L, et al. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Diseases Poverty. 2020;9(1). doi: 10.1186/s40249-020-00668-5
   PubMed Web of Science ®Google Scholar
• Zhao S, Feng Y, Hu J, et al. Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China. Sci Rep. 2018;8(1):12273. doi: 10.1038/s41598-018-29202-2
   PubMedGoogle Scholar
• Zheng S, Wu J, Hao J, et al. Epidemic Characteristics of HIV Drug Resistance in Hefei, Anhui Province. Pathogens. 2022;11(8):11. doi: 10.3390/pathogens11080866
   Web of Science ®Google Scholar
• Liu M, He XQ, Deng RN, et al. Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China. HIV Med. 2022;23(Suppl S1):95–105. doi: 10.1111/hiv.13253
   PubMedGoogle Scholar
• Zeng R, Ren D, Gong X, et al. HIV-1 Genetic Diversity and High Prevalence of Pretreatment Drug Resistance in Tianjin, China. AIDS Res Hum Retroviruses. 2020;36(10):852–861. doi: 10.1089/aid.2020.0056
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu L, Sun M, et al. An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. PLoS One. 2017;12(2):e0165110. doi: 10.1371/journal.pone.0165110
   PubMed Web of Science ®Google Scholar
• WHO. Surveillance of HIV drug resistance in adults initiating antiretroviral therapy (pre-treatment HIV drug resistance). 2014. Available from: https://www.who.int/publications/i/item/9789241507196
   Google Scholar
• WHO. HIV drug resistance. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance
   Google Scholar
• Zhang M, Ma Y, Wang G, et al. The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021. J antimicrob chemother. 2024;79:526–530. doi: 10.1093/jac/dkad370
   PubMed Web of Science ®Google Scholar
• Mbuagbaw L, Garcia C, Brenner B, et al. Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use. Lancet HIV. 2023;10(10):e684–e689. doi: 10.1016/s2352-3018(23)00173-x
   PubMed Web of Science ®Google Scholar
• Kosakovsky Pond SL, Weaver S, Leigh Brown AJ, et al. HIV-TRACE (TRAnsmission Cluster Engine): a Tool for Large Scale Molecular Epidemiology of HIV-1 and Other Rapidly Evolving Pathogens. Mol Biol Evol. 2018;35(7):1812–1819. doi: 10.1093/molbev/msy016
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance. 2012. Available from: https://iris.who.int/bitstream/handle/10665/77349/9789241504768_eng.pdf?sequence=1
   Google Scholar
• Zhang F, Liang B, Liang X, et al. Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China. Front genet. 2021;12:12. doi: 10.3389/fgene.2021.688292
   Web of Science ®Google Scholar
• Mazzuti L, Melengu T, Falasca F, et al. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naive patients: A single-centre experience. J Glob Antimicrob Resist. 2020;20:298–303. doi: 10.1016/j.jgar.2019.08.024
   PubMed Web of Science ®Google Scholar
• Liu Y, Li H, Wang X, et al. Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses. Infect Genet Evol. 2020;77:104098. doi: 10.1016/j.meegid.2019.104098
   PubMed Web of Science ®Google Scholar
• Sui H, Gui T, Jia L, et al. Different frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive study. PLoS One. 2014;9(3):e91803. doi: 10.1371/journal.pone.0091803
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen L, Chaillon A, et al. The dynamics of the HIV epidemic among men who have sex with men (MSM) from 2005 to 2012 in Shenzhen, China. Sci Rep. 2016;6(1):28703. doi: 10.1038/srep28703
   PubMedGoogle Scholar
• Gan M, Zheng S, Hao J, et al. The prevalence of CRF55_01B among HIV-1 strain and its connection with traffic development in China. Emerg Microbes Infect. 2021;10(1):256–265. doi: 10.1080/22221751.2021.1884004
   PubMed Web of Science ®Google Scholar
• Han J, Zhou Y, Ma Y, et al. A New HIV-1 K28E32-Reverse Transcriptase Variant Associated with the Rapid Expansion of CRF07_BC among Men Who Have Sex with Men. Microbiol Spectr. 2022;10(5):e0254522. doi: 10.1128/spectrum.02545-22
   PubMed Web of Science ®Google Scholar
• Wan Z, Zhang C. How to report and make sense of a new HIV-1 circulating recombinant form?. Front Microbiol. 2024;15:1343143. doi: 10.3389/fmicb.2024.1343143
   PubMed Web of Science ®Google Scholar
• Han X, An M, Zhang W, et al. Genome Sequences of a Novel HIV-1 Circulating Recombinant Form, CRF55_01B, Identified in China. Genome Announc. 2013;1(1):1. doi: 10.1128/genomeA.00050-12
   Google Scholar
• Zhao J, Cai W, Zheng C, et al. Origin and outbreak of HIV-1 CRF55_01B among MSM in Shenzhen, China. J Acquir Immune Defic Syndr. 2014;66(3):e65–7. doi: 10.1097/QAI.0000000000000144
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang M, Wang J, et al. Efficacy of Efavirenz-Based Regimen in Antiretroviral-Naïve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2022;12(1):245–255. doi: 10.1007/s40121-022-00723-8
   PubMed Web of Science ®Google Scholar